Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Conditions
Keywords
Melanoma, Cutaneous Melanoma, Metastatic Melanoma
Brief summary
The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. The trial duration will be approximately 15 months for each participant, including a 28-day screening period and estimated 4-month treatment and 10-month follow-up periods; however, the duration of the treatment and follow-up periods may vary for each participant. Participants will have regular check-ups while on treatment, with visits every week initially, and then every 3 weeks later in the trial.
Detailed description
This is a Phase 2, randomized, open-label, multicenter trial evaluating the efficacy and safety of acasunlimab as monotherapy and in combination with pembrolizumab in adult participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma who progressed on or after prior checkpoint inhibitor (CPI)-containing therapy. Participants will be randomized in a 1:1 ratio to receive acasunlimab and pembrolizumab or acasunlimab alone. Eligible participants must have received a minimum of 2 cycles of an approved anti-programmed cell death protein 1 (PD-1) containing therapy. Participants whose tumor harbors a B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600 mutation are eligible for the trial if they have received a BRAF-directed therapy (with or without a mitogen-activated protein kinase \[MEK\] inhibitor) prior to enrollment in the trial, unless the investigator has deemed a BRAF-directed therapy not clinically indicated. BRAF V600 mutational status must be determined by local assessment and documented.
Interventions
BIOLOGICALAcasunlimab
Intravenous (IV) infusion
BIOLOGICALPembrolizumab
IV infusion
Sponsors
Genmab
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Participants ≥ 18 years of age with histologically or cytologically confirmed diagnosis of relapsed/refractory, locally advanced unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, per American Joint Committee on Cancer (8th edition) staging. * Participant must have radiographic progression based on RECIST v1.1 on or following ≥ 1 prior systemic therapy, according to local and international guidelines, including a programmed cell death protein 1 blocking antibody (anti-PD-1) treatment or combination treatment containing an anti-PD-1. * Participant must have received a minimum of 2 cycles of an approved anti-PD-1 as monotherapy or a combination therapy containing an anti-PD-1. * Neoadjuvant and/or adjuvant systemic therapy count as the first line of prior systemic therapy if there is documented disease progression ≤ 6 months after completion of therapy. * Participants with a BRAF V600 mutation should have received prior BRAF-directed therapy (with or without a MEK inhibitor) prior to enrollment in the trial, unless deemed not clinically indicated by the Investigator due to concurrent medical condition or prior toxicity. * Participant has an Eastern Cooperative Oncology Group performance status of 0 or 1 within 7 days prior to Cycle 1 Day 1. Key
Exclusion criteria
* Participants with non-cutaneous or acral melanoma. * Participants with newly identified or known unstable or symptomatic central nervous system metastases or history of carcinomatous meningitis. Note: Other protocol-defined Inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to approximately 9 months | ORR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Response (TTR) | Up to approximately 9 months | TTR per RECIST v1.1 as assessed by the investigator was defined as the time from the date of first administration of trial drug to the first documented response of either CR or PR. |
| Duration of Response (DOR) | Up to approximately 9 months | DOR per RECIST v1.1 as assessed by the investigator was defined as the time from first documentation of objective response (PR or CR) that was subsequently confirmed, to the first documentation of disease progression or death due to any cause, whichever came first. |
| Progression-free Survival (PFS) | Up to approximately 9 months | PFS was defined as the time from the date of first administration of trial drug to the date of the first documented progression or death due to any cause, whichever occurred first. |
| Overall Survival (OS) | Up to approximately 9 months | OS was defined as the time from date of first administration of trial drug to date of death due to any cause. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Up to approximately 9 months | An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A TEAE was any AE that started after or worsened after drug administration. |
| Time to Treatment Discontinuation Due to AEs | Up to approximately 9 months | — |
Countries
Puerto Rico, United States
Contacts
STUDY_DIRECTORStudy Official
Genmab
Participant flow
Pre-assignment details
This trial was terminated. Two treatment arms were planned (Arm A: acasunlimab in combination with pembrolizumab and Arm B: acasunlimab). Arm A did not enroll any participants and is therefore not included in the tabular results. One participant was enrolled into Arm B. The study participant did not consent to publishing his/her individual data. As there was only one participant in this trial, no data are reported to protect and maintain participant privacy/confidentiality.
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
None listed